PERK Positive Control peptide (STJ504690)

SKU:
STJ504690-5

Shipping:
Free Shipping
Current Stock:
Applications: WB
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: PERK Positive Control is synthetically produced from the sequence and is suitable for use in western blot applications.
Formulation: Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is
Dilution Range: WB: 1:500
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Gene Symbol: EIF2AK3
Gene ID: 9451
Uniprot ID: E2AK3_HUMAN
Tissue Specificity Ubiquitous. A high level expression is seen in secretory tissues.
Post Translational Modifications Oligomerization of the N-terminal ER luminal domain by ER stress promotes EIF2AK3/PERK trans-autophosphorylation of the C-terminal cytoplasmic kinase domain at multiple residues including Thr-982 on the kinase activation loop. Autophosphorylated at Tyr-619 following endoplasmic reticulum stress, leading to activate its activity. Dephosphorylated at Tyr-619 by PTPN1/PTP1B, leading to inactivate its enzyme activity. Phosphorylation at Thr-802 by AKT (AKT1, AKT2 and/or AKT3) inactivates EIF2AK3/PERK. ADP-ribosylated by PARP16 upon ER stress, which increases kinase activity.
Function Metabolic-stress sensing protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) in response to various stress, such as unfolded protein response (UPR). Key effector of the integrated stress response (ISR) to unfolded proteins: EIF2AK3/PERK specifically recognizes and binds misfolded proteins, leading to its activation and EIF2S1/eIF-2-alpha phosphorylation. EIF2S1/eIF-2-alpha phosphorylation in response to stress converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, leading to a global attenuation of cap-dependent translation, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activators ATF4 and QRICH1, and hence allowing ATF4- and QRICH1-mediated reprogramming. The EIF2AK3/PERK-mediated unfolded protein response increases mitochondrial oxidative phosphorylation by promoting ATF4-mediated expression of COX7A2L/SCAF1, thereby increasing formation of respiratory chain supercomplexes. In contrast to most subcellular compartments, mitochondria are protected from the EIF2AK3/PERK-mediated unfolded protein response due to EIF2AK3/PERK inhibition by ATAD3A at mitochondria-endoplasmic reticulum contact sites. In addition to EIF2S1/eIF-2-alpha, also phosphorylates NFE2L2/NRF2 in response to stress, promoting release of NFE2L2/NRF2 from the BCR(KEAP1) complex, leading to nuclear accumulation and activation of NFE2L2/NRF2. Serves as a critical effector of unfolded protein response (UPR)-induced G1 growth arrest due to the loss of cyclin-D1 (CCND1). Involved in control of mitochondrial morphology and function.
Peptide Name Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3
Prkr-Like Endoplasmic Reticulum Kinase
Pancreatic Eif2-Alpha Kinase
Hspek
Protein Tyrosine Kinase Eif2ak3
Database Links Reactome: R-HSA-381042
Reactome: R-HSA-9700645
Reactome: R-HSA-9725370
Reactome: R-HSA-9755511
Cellular Localisation Endoplasmic Reticulum Membrane
Single-Pass Type I Membrane Protein
Localizes To The Localizes To Endoplasmic Reticulum Membrane
Also Present At Mitochondria-Endoplasmic Reticulum Contact Sites
Where It Interacts With Atad3a
Alternative Peptide Names Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 protein
Prkr-Like Endoplasmic Reticulum Kinase protein
Pancreatic Eif2-Alpha Kinase protein
Hspek protein
Protein Tyrosine Kinase Eif2ak3 protein
EIF2AK3 protein
PEK protein
PERK protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance